IPA Innovates with AI to Develop Next-Generation GLP-1 Therapies for Diabetes Treatment
Thursday, January 23, 2025
ImmunoPrecise Antibodies has created a new class of GLP-1 therapies for type 2 diabetes and obesity treatment, developed entirely through artificial intelligence (AI).
GLP-1 drugs are widely used to manage type 2 diabetes and obesity but often require frequent injections due to limited half-life.
IPA's AI platform, LENSai™, rapidly generated and optimised novel genetic sequences for GLP-1-like therapies, addressing the need for improved dosing regimens and patient experience.
This process, completed in just two weeks, highlights the capability of AI-driven systems to accelerate therapeutic development by identifying evolutionary patterns in biological data.
The LENSai™ platform analysed molecular features across species to identify and refine therapeutic sequences, improving their resistance to degradation and enhancing functionality.
Unlike traditional chemical modifications, IPA employed rational genetic engineering to increase the stability and performance of the peptides.
To support long-term therapeutic delivery, these GLP-1 constructs have been optimised for use with nucleic acid-based expression systems in collaboration with Aldevron.
The genetic engineering process has been tailored to improve gene expression and reduce immune response risks, allowing for efficient and stable in-body therapeutic production.
These innovative therapies, designed using IPA’s proprietary LENSai™ platform, aim to enhance efficacy, safety, and treatment longevity while improving patient convenience.
By optimising therapeutic design and delivery, the new constructs promise extended stability, reduced dosing frequency, and improved patient compliance. Current investigations are exploring the potential for transdermal delivery as a non-invasive alternative to injections.
IPA is investigating the possibility of delivering its GLP-1 therapies through a transdermal patch. This approach could offer a controlled release of the drug, improving absorption and convenience for patients.
AI-driven optimisations ensure compatibility with this method, laying the foundation for further development of non-invasive treatments.
IPA’s HYFT® patterns, central to the LENSai™ platform, are transforming the discovery and optimisation of biologics. These exclusive AI patterns enable in silico drug development, offering rapid and precise results while minimising resource consumption.
LENSai™ represents a significant advancement in therapeutic innovation, supporting end-to-end development processes that prioritise safety and efficacy.
With its focus on AI-driven biologics, IPA is paving the way for faster, more precise drug discovery and the development of next-generation therapies for diabetes and other diseases.
Source: ipatherapeutics.com
